Nurix Therapeutics Quarterly Balance Sheet
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics financial position
As of May 31, 2026, Nurix Therapeutics reported total assets of $535.5 million, down 9.5% from a year earlier against total liabilities of $132.9 million. Shareholders' equity stood at $402.6 million, or 75.2% of assets. The company held $67.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.34, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Nurix Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-05-31 | Q1 20262026-02-28 | Q4 20252025-11-30 | Q3 20252025-08-31 | Q2 20252025-05-31 | Q1 20252025-02-28 | Q4 20242024-11-30 | Q3 20242024-08-31 | Q2 20242024-05-31 | Q1 20242024-02-29 | Q4 20232023-11-30 | Q3 20232023-08-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 67.69M | 71.19M | 246.96M | 78.44M | 84.26M | 75.92M | 110.00M | 99.04M | 116.79M | 49.81M | 54.63M | 42.30M |
| Short-Term Investments | — | — | — | — | — | — | — | — | — | — | — | 216.55M |
| Receivables | — | — | — | — | 19.00M | — | 0 | — | — | — | — | 2.00M |
| Total Current Assets | 456.48M | 554.39M | 606.82M | 440.60M | 515.33M | 563.70M | 619.39M | 456.04M | 450.22M | 250.97M | 295.50M | 267.95M |
| Property, Plant & Equipment | 20.01M | 21.70M | 22.49M | 20.50M | 18.77M | 18.45M | 17.76M | 17.07M | 18.56M | 17.87M | 16.81M | 16.58M |
| Long-Term Investments | — | — | — | — | — | — | — | — | — | — | — | 9.88M |
| Total Assets | 535.54M | 636.13M | 688.13M | 522.47M | 591.55M | 615.04M | 669.34M | 513.60M | 511.03M | 312.67M | 355.60M | 308.19M |
| Accounts Payable | 12.21M | 10.29M | 11.21M | 8.61M | 5.95M | 8.40M | 11.48M | 3.92M | 2.81M | 5.92M | 6.40M | 2.19M |
| Total Current Liabilities | 72.02M | 92.20M | 86.47M | 82.35M | 75.61M | 89.99M | 95.85M | 86.30M | 80.78M | 87.62M | 86.96M | 61.49M |
| Total Liabilities | 132.91M | 155.24M | 149.39M | 150.22M | 143.95M | 134.13M | 142.35M | 136.74M | 140.34M | 143.93M | 155.10M | 74.38M |
| Shareholders' Equity | 402.63M | 480.89M | 538.75M | 372.25M | 447.60M | 480.92M | 526.99M | 376.86M | 370.69M | 168.75M | 200.49M | 233.82M |
| Retained Earnings | -1.18B | -1.09B | -1.00B | -925.00M | -838.58M | -795.12M | -738.77M | -680.22M | -631.26M | -586.72M | -545.20M | -503.24M |
| Net Cash (Debt) | 67.69M | 71.19M | 246.96M | 78.44M | 84.26M | 75.92M | 110.00M | 99.04M | 116.79M | 49.81M | 54.63M | 258.85M |
| Shares Outstanding | 103.70M | 103.40M | 101.81M | 76.87M | 76.43M | 76.23M | 75.87M | 67.08M | 64.36M | 49.14M | 48.72M | 48.50M |
This table shows 12 quarterly periods of Nurix Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NRIX's reporting calendar. What is a balance sheet?